ETH-LAD

ETH-LAD
Molecular structure of ETH-LAD
Chemical Nomenclature
Common names	ETH-LAD
Substitutive name	6-ethyl-6-nor-lysergic acid diethylamide
Systematic name	(6aR,9R)-N,N,7-triethyl-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
Class Membership
Psychoactive class	Psychedelic
Chemical class	Lysergamide
Routes of Administration
Oral Dosage WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section. DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy. Threshold 20 - 30 µg Light 30 - 60 µg Common 60 - 100 µg Strong 100 - 200 µg Heavy 200 µg + Duration Total 6 - 14 hours Onset 30 - 60 minutes Peak 4 - 7 hours Offset 4 - 5 hours After effects 2 - 5 hours

ETH-LAD, or 6-ethyl-6-nor-lysergic acid diethylamide, is a lysergamide psychedelic and an analogue of LSD. It was first described by Alexander Shulgin in his book TiHKAL.^[1] This compound is slightly more potent than LSD itself^[2] with an active dose reported at between 40 and 150 micrograms. It also has subtly different effects to LSD and is described as less demanding.

ETH-LAD, or 6-ethyl-6-nor-lysergic acid diethylamide, is a semi-synthethic alkaloid of the lysergamide famiy. ETH-LAD is a structural analogue of lysergic acid with an N,N-diethylamide functional group bound to RN of the chemical structure. This core polycyclic structure is an indole derivative and has tryptamine and phenethylamine groups embedded within it. ETH-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid).

ETH-LAD does not contain a methyl group substituted at R6 of its nor-lysgeric acid skeleton; this is represented by the nor- prefix. Instead, ETH-LAD is substituted at R6 with an ethyl group. At carbon 8 of the quinoline, a N,N-diethyl carboxamide is bound. ETH-LAD is a chiral compound with two stereocenters at R5 and R8. ETH-LAD, also called (+)-D-ETH-LAD, has an absolute configuration of (5R, 8R).

ETH-LAD likely acts as a 5-HT_2A partial agonist. The psychedelic effects are believed to come from ETH-LAD's efficacy at the 5-HT_2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

This subjective effect breakdown is a stub. As such, it may contain incomplete or wrong information and is still in progress. You can help by expanding it.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.

While the subjective effects are almost identical to that of LSD, in comparison to its structural relative LSZ it is reported to be more introspective stoning and sedating.

Physical effects

• Bodily control enhancement
• Nausea
• Pupil dilation
• Spontaneous tactile sensations
• Stimulation
• Tactile enhancement

Cognitive effects

• Analysis enhancement
• Conceptual thinking
• Delusions
• Déjà vu
• Emotion enhancement
• Feelings of interdependent opposites
• Immersion enhancement
• Memory suppression
  • Ego death
• Multiple thought streams
• Novelty enhancement
• Personal bias suppression
• Thought acceleration
• Thought loops
• Time distortion
• Unity and interconnectedness
• Wakefulness

Visual effects

Enhancements

• Colour enhancement
• Pattern recognition enhancement
• Visual acuity enhancement

Distortions

• After images
• Colour shifting
• Depth perception distortions
• Diffraction
• Drifting (melting, breathing, morphing and flowing)
• Scenery slicing
• Symmetrical texture repetition
• Tracers

Geometry

Hallucinatory states

ETH-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics. These effects include:

• Transformations
• Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)

Auditory effects

• Enhancements
• Distortions
• Hallucinations

Main articles: Research chemicals § Toxicity and harm potential & Responsible use § Hallucinogens

The toxicity and long-term health effects of recreational ETH-LAD use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because ETH-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried ETH-LAD suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

ETH-LAD is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of ETH-LAD are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). ETH-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of ETH-LAD all psychedelics will have a reduced effect.

This legality section is a stub. As such, it likely contains incomplete or wrong information. You can help by expanding it.

• United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.^[3]
• Switzerland - ETH-LAD is scheduled as of the 1st of December 2015.^[4]
• Latvia - ETH-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1th, 2015.^[5]

• Responsible use
• Lysergamide
• Psychedelic
• LSD
• AL-LAD
• LSZ

• ETH-LAD (Wikipedia)
• ETH-LAD (Tripsit)
• ETH-LAD (Bluelight)
• ETH-LAD experiences (Erowid)
• ETH-LAD (TiHKAL)

1. ↑ #12 ETH-LAD: 6-Norlysergic acid, 6,N,N-triethylamide; 6-Norlysergamide, 6,N,N-triethyl; 6,N,N-Triethyl-6-norlysergamide; N-(6)-Ethylnorlysergic acid, N,N-diethylamide; 9,10-Didehydro-N,N,6-triethylergoline-8β-carboxamide; N-Ethyl-nor-LSD | http://isomerdesign.com/PiHKAL/read.php?domain=tk&id=12
2. ↑ Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives | http://pubs.acs.org/doi/abs/10.1021/jm00147a022
3. ↑ Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted
4. ↑ Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeich nisverordnung, BetmVV - EDI) | https://www.admin.ch/opc/de/official-compilation/2015/5093.pdf
5. ↑ Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) | http://likumi.lv/doc.php?id=121086